S&P 500   3,891.43 (+2.11%)
DOW   31,596.50 (+2.15%)
QQQ   320.38 (+1.99%)
AAPL   124.89 (+2.99%)
MSFT   235.96 (+1.54%)
FB   260.96 (+1.30%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   544.52 (-0.74%)
BABA   239.77 (+0.85%)
CGC   34.60 (+5.65%)
GE   13.21 (+5.34%)
MU   93.91 (+2.60%)
NIO   49.20 (+7.47%)
AMD   85.03 (+0.62%)
T   28.38 (+1.76%)
F   11.94 (+2.05%)
ACB   11.21 (+6.56%)
DIS   195.88 (+3.62%)
BA   225.66 (+6.44%)
NFLX   548.24 (+1.74%)
BAC   35.66 (+2.74%)
S&P 500   3,891.43 (+2.11%)
DOW   31,596.50 (+2.15%)
QQQ   320.38 (+1.99%)
AAPL   124.89 (+2.99%)
MSFT   235.96 (+1.54%)
FB   260.96 (+1.30%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   544.52 (-0.74%)
BABA   239.77 (+0.85%)
CGC   34.60 (+5.65%)
GE   13.21 (+5.34%)
MU   93.91 (+2.60%)
NIO   49.20 (+7.47%)
AMD   85.03 (+0.62%)
T   28.38 (+1.76%)
F   11.94 (+2.05%)
ACB   11.21 (+6.56%)
DIS   195.88 (+3.62%)
BA   225.66 (+6.44%)
NFLX   548.24 (+1.74%)
BAC   35.66 (+2.74%)
S&P 500   3,891.43 (+2.11%)
DOW   31,596.50 (+2.15%)
QQQ   320.38 (+1.99%)
AAPL   124.89 (+2.99%)
MSFT   235.96 (+1.54%)
FB   260.96 (+1.30%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   544.52 (-0.74%)
BABA   239.77 (+0.85%)
CGC   34.60 (+5.65%)
GE   13.21 (+5.34%)
MU   93.91 (+2.60%)
NIO   49.20 (+7.47%)
AMD   85.03 (+0.62%)
T   28.38 (+1.76%)
F   11.94 (+2.05%)
ACB   11.21 (+6.56%)
DIS   195.88 (+3.62%)
BA   225.66 (+6.44%)
NFLX   548.24 (+1.74%)
BAC   35.66 (+2.74%)
S&P 500   3,891.43 (+2.11%)
DOW   31,596.50 (+2.15%)
QQQ   320.38 (+1.99%)
AAPL   124.89 (+2.99%)
MSFT   235.96 (+1.54%)
FB   260.96 (+1.30%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   544.52 (-0.74%)
BABA   239.77 (+0.85%)
CGC   34.60 (+5.65%)
GE   13.21 (+5.34%)
MU   93.91 (+2.60%)
NIO   49.20 (+7.47%)
AMD   85.03 (+0.62%)
T   28.38 (+1.76%)
F   11.94 (+2.05%)
ACB   11.21 (+6.56%)
DIS   195.88 (+3.62%)
BA   225.66 (+6.44%)
NFLX   548.24 (+1.74%)
BAC   35.66 (+2.74%)
Log in
NYSEAMERICAN:OCX

OncoCyte Stock Forecast, Price & News

$4.99
+0.07 (+1.42 %)
(As of 03/1/2021 10:31 AM ET)
Add
Compare
Today's Range
$4.99
Now: $4.99
$5.22
50-Day Range
$2.12
MA: $2.38
$2.63
52-Week Range
$1.15
Now: $4.99
$6.57
Volume8,715 shs
Average Volume1.59 million shs
Market Capitalization$335.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
OncoCyte logo

Headlines

Form 8-K OncoCyte Corp For: Feb 23 - StreetInsider.com
February 25, 2021 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515
Employees33
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-22,430,000.00

Miscellaneous

Market Cap$335.58 million
Next Earnings Date3/24/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

490th out of 1,962 stocks

Diagnostic Substances Industry

9th out of 32 stocks

Analyst Opinion: 1.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$4.99
+0.07 (+1.42 %)
(As of 03/1/2021 10:31 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Is OncoCyte a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte
or view top-rated stocks.

What stocks does MarketBeat like better than OncoCyte?

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OncoCyte?

OncoCyte saw a decrease in short interest in the month of January. As of January 29th, there was short interest totaling 1,990,000 shares, a decrease of 21.3% from the January 14th total of 2,530,000 shares. Based on an average trading volume of 2,200,000 shares, the short-interest ratio is currently 0.9 days.
View OncoCyte's Short Interest
.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for OncoCyte
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) announced its quarterly earnings data on Thursday, November, 12th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.01. The biotechnology company earned $0.56 million during the quarter, compared to analysts' expectations of $0.62 million.
View OncoCyte's earnings history
.

How has OncoCyte's stock price been impacted by COVID-19?

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OCX stock has increased by 142.5% and is now trading at $5.19.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OCX?

7 brokerages have issued 1-year target prices for OncoCyte's stock. Their forecasts range from $4.00 to $7.75. On average, they anticipate OncoCyte's share price to reach $5.11 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts' price targets for OncoCyte
or view top-rated stocks among Wall Street analysts.

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 61, Pay $312.5k)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Mr. William Annett, Advisor (Age 67, Pay $673.33k)
  • Ms. Padma Sundar, Sr. VP of Commercial
  • Dr. Douglas T. Ross M.D., Ph.D., Chief Medical Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 68)
  • Ms. Sara Riordan, Director of Medical Education

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of institutional and retail investors. Top institutional investors include Pura Vida Investments LLC (9.34%), BlackRock Inc. (5.21%), Northern Trust Corp (1.01%), Penbrook Management LLC (0.63%), Nuveen Asset Management LLC (0.36%) and GSA Capital Partners LLP (0.25%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte
.

Which institutional investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Barclays PLC.
View insider buying and selling activity for OncoCyte
or view top insider-selling stocks.

Which institutional investors are buying OncoCyte stock?

OCX stock was bought by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, BlackRock Inc., Penbrook Management LLC, Nisa Investment Advisors LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., Bank of New York Mellon Corp, and Virtu Financial LLC. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte
or or view top insider-buying stocks.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $5.19.

How much money does OncoCyte make?

OncoCyte has a market capitalization of $349.03 million. The biotechnology company earns $-22,430,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

How many employees does OncoCyte have?

OncoCyte employs 33 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

Where are OncoCyte's headquarters?

OncoCyte is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.